The innovative blood substitute successfully underwent clinical trials.
Kaluga region’s department of Russian Ministry of Health published data on product PAM-3, designed for treating ischemia of organs and tissues, also for an emergency blood transfusion due to battle injuries. PAM-3 is appropriate as for systematic operations as well as in extreme accidences, which requires an urgent blood supply, even in field conditions.
The product turns out in dry-sand form, it gives the opportunity to store it for a long period of time, in addition – without creation special conditions for transportation. PAM-3 is compatible with the majority of dissolvents, standard electrolytes, the order of reception varies according to instructions of the expert.
PAM-3 promotes entrance of the oxygen to the tissues and stimulates hemopoiesis in conditions of its deficit. This product has an ability to perform as a full substitute of erythrocytes of donor’s blood but in the meantime, it is unobligated to determine blood type and Rh factor. Blood-transmitted diseases sepsis threat is absent during usage.
At this moment there is a working procedure of PAM-3 production, which completely meets all requirements of Ministry of Health. Preclinical and clinical studies with healthy volunteers involved are conducted. During tests, an acceptability and a pharmacokinetics of the drug were analyzed, and also the safety of use in public is verified.